Validive (clonidine MBT) is a mucobuccal tablet (MBT) of clonidine based on the Lauriad® mucoadhesive technology. The Lauriad technology was developed for oral transmucosal drug delivery and significantly increases the mucous and salivary concentrations of the active ingredient it contains, with decreased systemic absorption. The tablet is placed under the patient's upper lip and remains there for several hours a day, releasing the active ingredient into the saliva.

Validive is designed to deliver high local concentrations of the active pharmaceutical ingredient clonidine, an agonist of alpha-2 adrenergic receptors (α2AR), to the oropharynx, the site of irradiation in the treatment of oropharyngeal cancer. In the oropharynx, α2AR are expressed on macrophages, immune cells that produce cytokines, the molecules that are responsible for the development of severe oral mucositis (Maria et al., 2017). A randomized, double-blinded Phase 2 trial confirmed Validive's mechanism of action and demonstrated:

  • reduced incidence of SOM
  • improvement of oral mucositis-related symptoms
  • decreased radiotherapy-related adverse events
  • a safety profile similar to placebo
  • strong compliance to treatment

Severe Oral Mucositis

Learn more about Severe Oral Mucositis (SOM).

Severe Oral Mucositis